Lung cancer is one of the most common solid tumors in the world as well as the leading cause of cancer death. There are still 940,000 former or current smokers sustaining high-risk of lung cancer in the United States. There are two main categories of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC contributes a large proportion (approximately 85%) of lung cancers. Chromosomal changes, tumor suppressor genes, oncogenes, signaling pathway disorders, up-regulation of receptor tyrosine kinases, growth factors and cellular markers, and the persistence of evolutionary pathways are all involved in the molecular pathogenesis of lung cancer.
CD-Genomics provides a predesigned lung cancer panel sequencing for targeted resequencing assay utilizing amplicon sequencing technology by illumina system, which covers a total of 23 hotspot genes associated with lung cancer. More efficient and accurate targeting of specific genes or mutations, and even low-frequency variants below 0.5% allele frequency can be detected. If necessary, you can choose genes that fit your requirements.
We provide customized bioinformatics analysis including:
CD Genomics provides the accurate and cost-effective lung cancer panel sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for lung cancer panel sequencing is outlined below.
|EGFR (+)||Afatinib, Erlotinib, Gefitinib, Dacomitinib|
|ALK (+)||Alectinib, Ceritinib, Crizotinib, Brigatinib|
|KRAS (+)||ERFR-TKIs resistance|
|ERBB2 (+)||Ado-trastuzumab Emtansine|
|BRAF (+)||Dabrafenib, Trametinib|
|RET (+)||Cabozantinib, Vandetanib|
For more information about the lung cancer panel or need other amplification requirements, please contact us.